Your browser doesn't support javascript.
loading
Virus-like particles of louping ill virus elicit potent neutralizing antibodies targeting multimers of viral envelope protein.
Tandavanitj, Rapeepat; Setthapramote, Chayanee; De Lorenzo, Giuditta; Sanchez-Velazquez, Ricardo; Clark, Jordan J; Rocchi, Mara; McInnes, Colin; Kohl, Alain; Patel, Arvind H.
Afiliación
  • Tandavanitj R; MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, Scotland, United Kingdom; Biologicals Research Group, Research and Development Institute, The Government Pharmaceutical Organization, Bangkok 10400, Thailand.
  • Setthapramote C; MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, Scotland, United Kingdom; Department of Clinical Pathology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok 10300, Thailand.
  • De Lorenzo G; MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, Scotland, United Kingdom.
  • Sanchez-Velazquez R; MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, Scotland, United Kingdom.
  • Clark JJ; MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, Scotland, United Kingdom.
  • Rocchi M; Moredun Research Institute, Midlothian EH26 0PZ, Scotland, United Kingdom.
  • McInnes C; Moredun Research Institute, Midlothian EH26 0PZ, Scotland, United Kingdom.
  • Kohl A; MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, Scotland, United Kingdom; Departments of Vector Biology and Tropical Disease Biology, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom.
  • Patel AH; MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH, Scotland, United Kingdom. Electronic address: Arvind.patel@glasgow.ac.uk.
Vaccine ; 42(9): 2429-2437, 2024 Apr 02.
Article en En | MEDLINE | ID: mdl-38458875
ABSTRACT
Louping ill virus (LIV) is a tick-borne flavivirus that predominantly causes disease in livestock, especially sheep in the British Isles. A preventive vaccine, previously approved for veterinary use but now discontinued, was based on an inactivated whole virion that likely provided protection by induction of neutralizing antibodies recognizing the viral envelope (E) protein. A major disadvantage of the inactivated vaccine was the need for high containment facilities for the propagation of infectious virus, as mandated by the hazard group 3 status of the virus. This study aimed to develop high-efficacy non-infectious protein-based vaccine candidates. Specifically, soluble envelope protein (sE), and virus-like particles (VLPs), comprised of the precursor of membrane and envelope proteins, were generated, characterized, and studied for their immunogenicity in mice. Results showed that the VLPs induced more potent virus neutralizing response compared to sE, even though the total anti-envelope IgG content induced by the two antigens was similar. Depletion of anti-monomeric E protein antibodies from mouse immune sera suggested that the neutralizing antibodies elicited by the VLPs targeted epitopes spanning the highly organized structure of multimer of the E protein, whereas the antibody response induced by sE focused on E monomers. Thus, our results indicate that VLPs represent a promising LIV vaccine candidate.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas / Virus de la Encefalitis Transmitidos por Garrapatas / Vacunas de Partículas Similares a Virus Límite: Animals Idioma: En Revista: Vaccine Año: 2024 Tipo del documento: Article País de afiliación: Tailandia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas / Virus de la Encefalitis Transmitidos por Garrapatas / Vacunas de Partículas Similares a Virus Límite: Animals Idioma: En Revista: Vaccine Año: 2024 Tipo del documento: Article País de afiliación: Tailandia